About PR. When Ph2 study of P completed I opined that a Ph2b would be necessary. I felt that the company was surprised by the reaction of mederate to severe and the higher dosage reaction. All positive. Ph2b will further study that. What will now happen is any thought of a deal for P will be delayed. This will give the bashers fodder. Long term this should enhance value. Short term probably go lower
